GRAIL Faces Class Action After Trial Failure
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Source: Globenewswire
- Severe Market Reaction: GRAIL, Inc. lost over $2.2 billion in market capitalization following the NHS-Galleri trial readout, with shares plummeting more than 50% the next day, reflecting strong investor disappointment and distrust in the company's future prospects.
- Legal Action Initiated: In response to the trial's failure to meet its primary endpoint, Hagens Berman has launched a securities class action lawsuit representing investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging violations of federal securities laws by the company and its executives.
- Disclosure Controversy: The lawsuit claims that GRAIL misled investors regarding the trial's design and expected outcomes, asserting that the three-year follow-up was sufficient to significantly reduce late-stage cancer diagnoses, while internal information suggested this timeframe might be inadequate to support trial success.
- Ongoing Investigation: Hagens Berman is investigating when GRAIL's management became aware of the need for a longer follow-up period and encourages individuals with knowledge to come forward to assist in holding the company and its executives accountable.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy GRAL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on GRAL
Wall Street analysts forecast GRAL stock price to fall
3 Analyst Rating
1 Buy
2 Hold
0 Sell
Moderate Buy
Current: 62.100
Low
38.00
Averages
60.86
High
83.71
Current: 62.100
Low
38.00
Averages
60.86
High
83.71
About GRAL
Grail, Inc. is a healthcare company focused on saving lives and shifting the paradigm in early cancer detection. The Company is focused on alleviating the global burden of cancer by using sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its multi-cancer early detection test, the Galleri test, is a commercially available screening test for early detection of multiple types of cancer. The Galleri test can be used to screen for cancer before a person becomes symptomatic, when cancer may be more easily treated and potentially curable. The Galleri test can indicate the origin of the cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
GRAIL Faces Class Action After Trial Failure
- Severe Market Reaction: GRAIL, Inc. lost over $2.2 billion in market capitalization following the NHS-Galleri trial readout, with shares plummeting more than 50% the next day, reflecting strong investor disappointment and distrust in the company's future prospects.
- Legal Action Initiated: In response to the trial's failure to meet its primary endpoint, Hagens Berman has launched a securities class action lawsuit representing investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging violations of federal securities laws by the company and its executives.
- Disclosure Controversy: The lawsuit claims that GRAIL misled investors regarding the trial's design and expected outcomes, asserting that the three-year follow-up was sufficient to significantly reduce late-stage cancer diagnoses, while internal information suggested this timeframe might be inadequate to support trial success.
- Ongoing Investigation: Hagens Berman is investigating when GRAIL's management became aware of the need for a longer follow-up period and encourages individuals with knowledge to come forward to assist in holding the company and its executives accountable.
See More
Notice of Class Action Lawsuit for GRAIL Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the true state of the NHS-Galleri trial, resulting in investor losses once the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- Investor Guidance: Investors are encouraged to select qualified counsel with proven success, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action lawsuit.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock plummeted by 50.55% on February 19, 2026, due to the failure to meet the primary endpoint of the NHS-Galleri trial, dropping from $101.53 to $50.21 per share, which undermines investor confidence and may affect future fundraising capabilities.
- Lawsuit Context: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of GRAIL investors, accusing the company and its executives of misleading investors regarding the NHS-Galleri cancer trial, potentially violating federal securities laws and increasing the legal risks faced by the company.
- Trial Design Controversy: GRAIL claimed that the NHS-Galleri trial was designed to last three years to reduce late-stage cancer cases, but the lawsuit argues that this timeframe was insufficient to demonstrate effectiveness, potentially diminishing the company's competitiveness in the early cancer detection market.
- Investor Actions: Investors are encouraged to apply to lead the case by August 4, 2026, indicating concerns over the company's future legal and financial outlook, which may impact GRAIL's market reputation and shareholder trust.
See More
Reminder for Grail Investors on Class Action Deadline
- Lawsuit Background: Grail's stock plummeted by 50.5% to $50.21 per share on February 20, 2026, after the NHS-Galleri trial failed to meet its primary endpoint, resulting in significant investor losses.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by August 4, 2026, alleging that the company made misleading statements and failed to disclose critical adverse information during the class period from May 13, 2025, to February 19, 2026.
- Management Confidence Issues: The lawsuit claims that management's confidence in the trial's initial results was misplaced, ignoring unreleased trend data, which misled investors regarding the company's prospects.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing necessary contact details for legal support.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against GRAIL, Inc., alleging violations of federal securities laws on behalf of all investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026.
- False Statements Allegation: The complaint claims that the defendants made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects.
- Investor Rights Protection: Affected investors have until August 4, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors' rights are protected without upfront costs.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman is recognized for its success in recovering hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duties by its executives, which may lead shareholders to seek corporate reforms and fund recovery.
- Financial Performance Under Scrutiny: A recent securities fraud class action alleges that Badger Meter misled investors into believing its financial performance was driven by sustainable demand, while in reality, it masked weakening demand trends.
- Impact of Declining Performance: Following a series of disappointing quarterly announcements in 2025 and 2026, Badger Meter's stock price experienced significant declines, severely undermining investor confidence in the company's future growth prospects and resulting in substantial losses for shareholders.
- Legal Action Recommendations: Shareholders who hold Badger Meter stock are encouraged to participate in the investigation to seek no-cost corporate reforms and court-approved incentives, aiming to protect their interests and pursue potential compensation.
See More
GRAIL Faces Class Action After Trial Failure
- Severe Market Reaction: GRAIL, Inc. lost over $2.2 billion in market capitalization following the NHS-Galleri trial readout, with shares plummeting more than 50% the next day, reflecting strong investor disappointment and distrust in the company's future prospects.
- Legal Action Initiated: In response to the trial's failure to meet its primary endpoint, Hagens Berman has launched a securities class action lawsuit representing investors who purchased GRAIL stock between May 13, 2025, and February 19, 2026, alleging violations of federal securities laws by the company and its executives.
- Disclosure Controversy: The lawsuit claims that GRAIL misled investors regarding the trial's design and expected outcomes, asserting that the three-year follow-up was sufficient to significantly reduce late-stage cancer diagnoses, while internal information suggested this timeframe might be inadequate to support trial success.
- Ongoing Investigation: Hagens Berman is investigating when GRAIL's management became aware of the need for a longer follow-up period and encourages individuals with knowledge to come forward to assist in holding the company and its executives accountable.
See More
Notice of Class Action Lawsuit for GRAIL Shareholders
- Class Action Notice: Rosen Law Firm reminds investors who purchased GRAIL (NASDAQ: GRAL) common stock between May 13, 2025, and February 19, 2026, to apply as lead plaintiffs by August 4, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The complaint alleges that GRAIL's defendants provided overly positive statements while concealing significant adverse facts regarding the true state of the NHS-Galleri trial, resulting in investor losses once the truth was revealed.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked No. 1 by ISS Securities Class Action Services in 2017, highlighting its successful track record in this field.
- Investor Guidance: Investors are encouraged to select qualified counsel with proven success, avoiding firms that merely act as intermediaries, to ensure effective legal representation in the class action lawsuit.
See More
GRAIL Faces Class Action Lawsuit for Securities Fraud
- Stock Price Plunge: GRAIL's stock plummeted by 50.55% on February 19, 2026, due to the failure to meet the primary endpoint of the NHS-Galleri trial, dropping from $101.53 to $50.21 per share, which undermines investor confidence and may affect future fundraising capabilities.
- Lawsuit Context: A class action lawsuit has been filed by Bleichmar Fonti & Auld LLP on behalf of GRAIL investors, accusing the company and its executives of misleading investors regarding the NHS-Galleri cancer trial, potentially violating federal securities laws and increasing the legal risks faced by the company.
- Trial Design Controversy: GRAIL claimed that the NHS-Galleri trial was designed to last three years to reduce late-stage cancer cases, but the lawsuit argues that this timeframe was insufficient to demonstrate effectiveness, potentially diminishing the company's competitiveness in the early cancer detection market.
- Investor Actions: Investors are encouraged to apply to lead the case by August 4, 2026, indicating concerns over the company's future legal and financial outlook, which may impact GRAIL's market reputation and shareholder trust.
See More
Reminder for Grail Investors on Class Action Deadline
- Lawsuit Background: Grail's stock plummeted by 50.5% to $50.21 per share on February 20, 2026, after the NHS-Galleri trial failed to meet its primary endpoint, resulting in significant investor losses.
- Class Action Details: Investors are reminded to file a lead plaintiff motion by August 4, 2026, alleging that the company made misleading statements and failed to disclose critical adverse information during the class period from May 13, 2025, to February 19, 2026.
- Management Confidence Issues: The lawsuit claims that management's confidence in the trial's initial results was misplaced, ignoring unreleased trend data, which misled investors regarding the company's prospects.
- Legal Consultation Information: Investors seeking more information or wishing to participate in the lawsuit can contact Glancy Prongay Wolke & Rotter LLP, providing necessary contact details for legal support.
See More
Class Action Lawsuit Filed Against GRAIL, Inc.
- Lawsuit Background: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against GRAIL, Inc., alleging violations of federal securities laws on behalf of all investors who purchased GRAIL securities between May 13, 2025, and February 19, 2026.
- False Statements Allegation: The complaint claims that the defendants made materially false and misleading statements regarding the likelihood of achieving the primary endpoint in the NHS-Galleri trial, concealing adverse facts that misled investors about the company's prospects.
- Investor Rights Protection: Affected investors have until August 4, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors' rights are protected without upfront costs.
- Law Firm's Advantage: Bronstein, Gewirtz & Grossman is recognized for its success in recovering hundreds of millions for investors nationwide, focusing on restoring investor capital and ensuring corporate accountability to uphold market integrity.
See More
Badger Meter Shareholder Investigation Raises Concerns
- Shareholder Investigation Launched: Grabar Law Office is investigating Badger Meter, Inc. (NYSE: BMI) for potential breaches of fiduciary duties by its executives, which may lead shareholders to seek corporate reforms and fund recovery.
- Financial Performance Under Scrutiny: A recent securities fraud class action alleges that Badger Meter misled investors into believing its financial performance was driven by sustainable demand, while in reality, it masked weakening demand trends.
- Impact of Declining Performance: Following a series of disappointing quarterly announcements in 2025 and 2026, Badger Meter's stock price experienced significant declines, severely undermining investor confidence in the company's future growth prospects and resulting in substantial losses for shareholders.
- Legal Action Recommendations: Shareholders who hold Badger Meter stock are encouraged to participate in the investigation to seek no-cost corporate reforms and court-approved incentives, aiming to protect their interests and pursue potential compensation.
See More
